Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.
Rustgi. Vinod V
Key Findings
- Combining thymosin‑alpha‑1 with peginterferon is being tested as a way to help hard‑to‑treat hepatitis C patients.
- Preliminary ideas suggest the combo could be more effective, but concrete results are still pending.
- A phase 3 trial in the United States is currently underway to evaluate safety and efficacy.
Practical Outcomes
- At this stage the information is mainly informational – it signals that thymosin‑alpha‑1 might have therapeutic potential, but there’s no actionable protocol, dosage, or safety data for self‑experimentation. Biohackers should wait for the phase 3 results before considering any use.
Summary
This study looks at adding thymosin‑alpha‑1 to standard pegylated interferon therapy for people with hepatitis C who didn’t respond to usual treatment. It’s still early – the trial is ongoing and no clear dosing or success numbers are given yet, so it’s not something you can apply right now.
Abstract
The worldwide spread of hepatitis C virus is enormous; chronic hepatitis C virus infection is a leading cause of liver cirrhosis and hepatocellular carcinoma. While treatment options have improved substantially over the last decade, responses are still disappointing, particularly in certain difficult-to-treat groups such as patients who are immunosuppressed or have decompensated disease. Preliminary studies have indicated that combined treatment strategies may provide effective approaches for the future. The combination of thymalfasin with pegylated interferon is currently a promising option for the treatment of patients with chronic hepatitis C virus infection. An ongoing phase 3 study in the USA should provide much needed data to improve the outcome for these patients.
Study Information
pubmed
2004
2004-12-01T00:00:00.000Z
10.1111/j.1440-1746.2004.03632.x
15
4